We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amdocs Q3 Earnings Surpass Expectations, Revenues Fall Y/Y
Read MoreHide Full Article
Key Takeaways
Amdocs posted Q3 EPS of $1.72, topping estimates and rising 6.2% year over year.
DOX's Q3 revenues fell 8.4% Y/Y but rose 3.5% excluding phased-out operations.
FY25 EPS growth is now guided at 8-9%, with free cash flow expected at $710-$730 million.
Amdocs Limited (DOX - Free Report) reported better-than-expected third-quarter fiscal 2025 results. The company posted non-GAAP earnings of $1.72 per share, which came above the midpoint of the management’s guidance of $1.68-$1.74 and increased 6.2% year over year. The figure also exceeded the Zacks Consensus Estimate of $1.71.
In the trailing four quarters, DOX’s earnings surpassed the Zacks Consensus Estimate thrice while matching once, with an average surprise of 1.5%.
Amdocs’ third-quarter revenues of $1.14 billion surpassed the consensus mark of $1.13 billion. However, compared with the year-ago quarter, revenues were down 8.4% on a reported basis due to the phase-out of certain business activities. Excluding the effect of phase-out business activities, revenues were up 3.5% year over year in pro forma constant currency.
Amdocs reported a decline in revenues across North America and the Rest of the World (RoW) due to the phase-out of certain business activities. North America reported revenues of $745.4 million (65.1% of total revenues), which plunged 10.1% year over year. RoW revenues (18.3% of total revenues) declined 14.5% year over year to $209.6 million.
Europe revenues (16.6% of total revenues) of $189.4 million increased 7.7% year over year. Our model estimates for North America, RoW and Europe were pinned at $736.8 million, $234.2 million and $159.3 million, respectively.
Managed services revenues rose 4.1% year over year to $771.5 million. The company ended the third quarter of fiscal 2025 with a 12-month backlog of $4.15 billion, down $20 million sequentially. Our model estimates for managed services revenues and backlog were pegged at $701.3 million and $3.97 billion, respectively.
The non-GAAP operating income increased 5.3% year over year to $244.7 million, while the operating margin expanded 280 basis points (bps) to 21.4%.
Amdocs’ Balance Sheet & Cash Flow
Amdocs had cash and short-term investments of $342.5 million as of June 30, 2025, compared with $324 million as of March 31, 2025. Long-term debt was $646.7 million as of June 30, 2025, almost flat to the March 31, 2025’s level of 646.6 million.
During the third quarter, it generated an operating cash flow of $241.2 million and a free cash flow of $211.8 million. In the first three quarters of fiscal 2025, it generated operating cash flow and free cash flow of $519.3 million and $446.5 million, respectively.
Amdocs Updates Guidance for Q4 & FY2025
Amdocs initiated guidance for the fourth quarter and updated the outlook for fiscal 2025. For the fourth quarter, the company expects revenues to be in the band of $1.125-$1.165 billion (mid-point $1.145 billion). The Zacks Consensus Estimate for revenues is pegged at $1.14 billion, suggesting a year-over-year decline of 9.6%.
Amdocs expects non-GAAP earnings per share to be between $1.79 and $1.85. The Zacks Consensus Estimate for earnings is pegged at $1.79 per share, indicating a year-over-year rise of 5.3%.
For fiscal 2025, Amdocs updated revenue decline rate guidance to 9.0-10.0% from 9.1-10.9% forecasted previously. The mid-point of the new guidance range suggests a decline of 9.5%. The Zacks Consensus Estimate for revenues is pegged at $4.51 billion, suggesting a year-over-year decline of 9.9%.
Non-GAAP operating margin is still anticipated to be in the range of 21.1-21.7% for fiscal 2025. Non-GAAP earnings per share are now expected to grow in the band of 8.0-9.0%, up from 6.5-10.5% forecasted previously. The Zacks Consensus Estimate for earnings is pegged at $6.96 per share, indicating a year-over-year rise of 8.1%.
The company continues to expect free cash flow between $710 million and $730 million.
The Zacks Consensus Estimate for CDW’s 2025 earnings has been revised upwards by 2 cents to $9.73 per share in the past 30 days, implying a year-over-year increase of 2.2%. CDW shares have lost 4.9% year to date.
The Zacks Consensus Estimate for Genpact’s 2025 earnings has been revised by 2 cents to $3.49 per share over the past 30 days and suggests a year-over-year increase of 6.4%. Genpact shares have lost 1.8% year to date.
The Zacks Consensus Estimate for EXL Service’s 2025 earnings has been revised upward by 2 cents to $1.90 per share in the past seven days, calling for a 15.2% year-over-year increase. EXL Service shares have lost 3.7% year to date.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amdocs Q3 Earnings Surpass Expectations, Revenues Fall Y/Y
Key Takeaways
Amdocs Limited (DOX - Free Report) reported better-than-expected third-quarter fiscal 2025 results. The company posted non-GAAP earnings of $1.72 per share, which came above the midpoint of the management’s guidance of $1.68-$1.74 and increased 6.2% year over year. The figure also exceeded the Zacks Consensus Estimate of $1.71.
In the trailing four quarters, DOX’s earnings surpassed the Zacks Consensus Estimate thrice while matching once, with an average surprise of 1.5%.
Amdocs’ third-quarter revenues of $1.14 billion surpassed the consensus mark of $1.13 billion. However, compared with the year-ago quarter, revenues were down 8.4% on a reported basis due to the phase-out of certain business activities. Excluding the effect of phase-out business activities, revenues were up 3.5% year over year in pro forma constant currency.
Amdocs Limited Price, Consensus and EPS Surprise
Amdocs Limited price-consensus-eps-surprise-chart | Amdocs Limited Quote
Amdocs’ Q3 Details
Amdocs reported a decline in revenues across North America and the Rest of the World (RoW) due to the phase-out of certain business activities. North America reported revenues of $745.4 million (65.1% of total revenues), which plunged 10.1% year over year. RoW revenues (18.3% of total revenues) declined 14.5% year over year to $209.6 million.
Europe revenues (16.6% of total revenues) of $189.4 million increased 7.7% year over year. Our model estimates for North America, RoW and Europe were pinned at $736.8 million, $234.2 million and $159.3 million, respectively.
Managed services revenues rose 4.1% year over year to $771.5 million. The company ended the third quarter of fiscal 2025 with a 12-month backlog of $4.15 billion, down $20 million sequentially. Our model estimates for managed services revenues and backlog were pegged at $701.3 million and $3.97 billion, respectively.
The non-GAAP operating income increased 5.3% year over year to $244.7 million, while the operating margin expanded 280 basis points (bps) to 21.4%.
Amdocs’ Balance Sheet & Cash Flow
Amdocs had cash and short-term investments of $342.5 million as of June 30, 2025, compared with $324 million as of March 31, 2025. Long-term debt was $646.7 million as of June 30, 2025, almost flat to the March 31, 2025’s level of 646.6 million.
During the third quarter, it generated an operating cash flow of $241.2 million and a free cash flow of $211.8 million. In the first three quarters of fiscal 2025, it generated operating cash flow and free cash flow of $519.3 million and $446.5 million, respectively.
Amdocs Updates Guidance for Q4 & FY2025
Amdocs initiated guidance for the fourth quarter and updated the outlook for fiscal 2025. For the fourth quarter, the company expects revenues to be in the band of $1.125-$1.165 billion (mid-point $1.145 billion). The Zacks Consensus Estimate for revenues is pegged at $1.14 billion, suggesting a year-over-year decline of 9.6%.
Amdocs expects non-GAAP earnings per share to be between $1.79 and $1.85. The Zacks Consensus Estimate for earnings is pegged at $1.79 per share, indicating a year-over-year rise of 5.3%.
For fiscal 2025, Amdocs updated revenue decline rate guidance to 9.0-10.0% from 9.1-10.9% forecasted previously. The mid-point of the new guidance range suggests a decline of 9.5%. The Zacks Consensus Estimate for revenues is pegged at $4.51 billion, suggesting a year-over-year decline of 9.9%.
Non-GAAP operating margin is still anticipated to be in the range of 21.1-21.7% for fiscal 2025. Non-GAAP earnings per share are now expected to grow in the band of 8.0-9.0%, up from 6.5-10.5% forecasted previously. The Zacks Consensus Estimate for earnings is pegged at $6.96 per share, indicating a year-over-year rise of 8.1%.
The company continues to expect free cash flow between $710 million and $730 million.
DOX’s Zacks Rank & Stocks to Consider
Currently, Amdocs carries a Zacks Rank #3 (Hold).
Some better-ranked stocks that investors can consider in the Zacks Computers - IT Services industry are CDW (CDW - Free Report) , Genpact (G - Free Report) and EXL Service (EXLS - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for CDW’s 2025 earnings has been revised upwards by 2 cents to $9.73 per share in the past 30 days, implying a year-over-year increase of 2.2%. CDW shares have lost 4.9% year to date.
The Zacks Consensus Estimate for Genpact’s 2025 earnings has been revised by 2 cents to $3.49 per share over the past 30 days and suggests a year-over-year increase of 6.4%. Genpact shares have lost 1.8% year to date.
The Zacks Consensus Estimate for EXL Service’s 2025 earnings has been revised upward by 2 cents to $1.90 per share in the past seven days, calling for a 15.2% year-over-year increase. EXL Service shares have lost 3.7% year to date.